
Biogen (BIIB) Stock Forecast & Price Target
Biogen (BIIB) Analyst Ratings
Bulls say
Biogen is expected to see significant revenue growth driven by its product portfolio, with combined sales projected to reach $689 million in 2025 and anticipated to increase at a mid- to high-teens percentage through 2028. The company's acquisition of APLS for $5.6 billion is poised to enhance its nephrology and immunology segments, further adding value to its shares and positioning it favorably for upcoming product developments. Additionally, Biogen's diverse range of offerings, including sales from Empaveli and the expected increase in revenues from Syfovre, contributes to a positive outlook, with forecasts suggesting peak revenues could approach $2.5 billion by 2038.
Bears say
Biogen faces significant challenges with its revenue-generating franchises, particularly with the anticipated decline in its multiple sclerosis franchise, which contributed 40% of total revenue in 2025. The company's newer products, including Spinraza and Leqembi, are at risk of lower-than-expected sales due to increased competition and potential reimbursement hurdles, while the commercial uptake of Syfovre is hampered by heavy reliance on free goods, gross-to-net pressures, and slow market adoption. Additionally, there are concerns regarding pipeline failures, management distractions, and unfavorable developments related to its collaboration agreements, all contributing to a negative outlook for Biogen's stock.
This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.
Biogen (BIIB) Analyst Forecast & Price Prediction
Start investing in Biogen (BIIB)
Order type
Buy in
Order amount
Est. shares
0 shares